Bristol-Myers Squibb Co  

(Public, OTCMKTS:BMYMP)   Watch this stock  
Find more results for NYSE:BMY-
-36.83 (-3.22%)
Apr 20 - Close
OTCMKTS data delayed by 15 mins - Disclaimer
Currency in USD
Range 1,107.34 - 1,107.34
52 week 750.00 - 1,165.00
Open 1,107.34
Vol / Avg. 1.00/8.00
Mkt cap 105.41B
P/E 921.68
Div/yield 0.37/0.13
EPS 1.20
Shares 4,212.00
Beta -12.21
Inst. own 28707793%
May 5, 2015
Bristol-Myers Squibb Co Annual Shareholders Meeting - 10:00AM EDT - Add to calendar
Apr 28, 2015
Q1 2015 Bristol-Myers Squibb Co Earnings Call - 11:00AM EDT - Add to calendar
Apr 28, 2015
Q1 2015 Bristol-Myers Squibb Co Earnings Release - 9:30AM EDT - Add to calendar
Mar 3, 2015
Bristol-Myers Squibb Co at Cowen Health Care Conference
Feb 12, 2015
Bristol-Myers Squibb Co at Leerink Global Healthcare Conference
Jan 27, 2015
Q4 2014 Bristol-Myers Squibb Co Earnings Release
Jan 27, 2015
Q4 2014 Bristol-Myers Squibb Co Earnings Call

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin 0.63% 12.78%
Operating margin -1.41% 11.41%
EBITD margin - 24.69%
Return on average assets 0.32% 5.61%
Return on average equity 0.35% 13.36%
Employees 25,000 -
CDP Score - 98 B


NEW YORK, NY 10154
United States - Map
+1-212-5464000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

About Company - Wikipedia


Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products on a global basis. The Company's products are sold across the world, to wholesalers, retail pharmacies, hospitals, Government entities and the medical profession. It manufactures products in the United States, Puerto Rico and in over six foreign countries. Its pharmaceutical products include chemically-synthesized drugs or small molecules, and products produced from biological processes. Its products in therapeutic classes: virology, including human immunodeficiency virus (HIV) infection; oncology; neuroscience; metabolics; immunoscience, and cardiovascular. Its product F001287 is a preclinical, small-molecule IDO1-inhibitor. It offers an indoleamine 2, 3-dioxygenase (IDO) or tryptophan 2, 3-dioxygenase (TDO) discovery program that includes its IDO-selective, IDO/TDO dual and TDO-selective compound libraries.

Officers and directors

Charles A. Bancroft Chief Financial Officer, Executive Vice President
Age: 55
Louis S Schmukler President - Global Manufacturing and Supply
Age: 59
Giovanni Caforio M.D. Chief Executive Officer, Director
Age: 50
Francis M. Cuss Executive Vice President, Chief Scientific Officer
Age: 60
Sandra Leung Executive Vice President, General Counsel and Corporate Secretary
Age: 54
Trading Activity - Yahoo Finance
Paul von Autenried Senior Vice President - Enterprise Services, Chief Information Officer
Age: 53
Anne Nielsen Senior Vice President, Chief Compliance and Ethics Officer
Age: 54
Joseph C. Caldarella Senior Vice President, Corporate Controller
Age: 59
Trading Activity - Yahoo Finance
Ann Powell Judge Senior Vice President - Global Human Resources
Age: 49
John E. Elicker Senior Vice President - Public Affairs
Age: 55